Bethanne Carson
Psychiatric/Mental Health · Lake Charles, LANPI 1780931154
Payments from drug & device makers
Across 754 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$969
- Neurocrine Biosciences, Inc.$685
- plus $5K from 23 others
What the payments were for
- Food & beverage$12,12499%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 148 | $2,164 |
| Otsuka America Pharmaceutical, Inc. | 73 | $1,198 |
| Alkermes, Inc. | 72 | $1,146 |
| Johnson & Johnson | 53 | $1,022 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $969 |
| Neurocrine Biosciences, Inc. | 38 | $685 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $587 |
| Teva Pharmaceuticals USA, Inc. | 31 | $552 |
| Corium, LLC | 31 | $527 |
| Axsome Therapeutics, Inc. | 35 | $521 |
| Vanda Pharmaceuticals Inc. | 27 | $476 |
| Sunovion Pharmaceuticals Inc. | 36 | $434 |
| Lundbeck LLC | 20 | $353 |
| Idorsia Pharmaceuticals US Inc | 16 | $335 |
| Indivior Inc. | 22 | $274 |
| Noven Therapeutics, LLC | 11 | $164 |
| Biogen | 1 | $111 |
| Merck | 7 | $111 |
| E.r. Squibb & Sons, L.L.C. | 5 | $111 |
| Supernus Pharmaceuticals, Inc. | 6 | $109 |
| Tris Pharma Inc | 6 | $98 |
| Ironshore Pharmaceuticals Inc. | 4 | $64 |
| Sage Therapeutics, LLC | 3 | $63 |
| Eisai Inc. | 4 | $54 |
| Bausch Health US, LLC | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Noven Pharmaceuticals, Inc. | 1 | $18 |
| Bioxcel Therapeutics, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,257 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $280,323 |
| Invega SustennaPaliperidone Palmitate | 33 | $114,416 |
| VraylarCariprazine Hcl | 48 | $68,917 |
| RexultiBrexpiprazole | 28 | $54,445 |
| BelsomraSuvorexant | 31 | $15,235 |
| TrintellixVortioxetine Hydrobromide | 21 | $14,663 |
| XanaxAlprazolam | 14 | $7,784 |
| Asenapine Maleate | 18 | $5,019 |
| Aripiprazole | 103 | $4,996 |
| Duloxetine Hcl | 196 | $3,746 |
| Vilazodone Hcl | 32 | $3,566 |
| Bupropion XlBupropion Hcl | 118 | $2,931 |
| Quetiapine Fumarate | 155 | $2,608 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $2,229 |
| Zolpidem Tartrate ErZolpidem Tartrate | 24 | $2,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $685 | $280,32333 claims |
| Johnson & JohnsonInvega Sustenna | $1,022 | $114,41633 claims |
| AbbVieVraylar | $2,164 | $68,91748 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,198 | $54,44528 claims |
| MerckBelsomra | $111 | $15,23531 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $587 | $14,66321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lake Charles
- Sattaria DilksLake Charles$57K
- Michelle DyerLake Charles$33K
- Erica HessiferLake Charles$13K
- Candyce BrownLake Charles$13K
- Morgan UnserLake Charles$9K
- Eric RachalLake Charles$9K
- Lori KayLake Charles$9K
- Valarie ClarkLake Charles$8K
- Julie DyrekLake Charles$8K
- Halie OryLake Charles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.